CT radiomic signature predicts survival and chemotherapy benefit in stage I and II HPV-associated oropharyngeal carcinoma.

ABSTRACT: Chemoradiation is a common therapeutic regimen for human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma (OPSCC). However, not all patients benefit from chemotherapy, especially patients with low-risk characteristics. We aim to develop and validate a prognostic and predictive radiomic image signature (pRiS) to inform survival and chemotherapy benefit using computed tomography (CT) scans from 491 stage I and II HPV-associated OPSCC, which were divided into three cohorts D₁-D₃. The prognostic performance of pRiS was evaluated on two test sets (D₂, n = 162; D₃, n = 269) using concordance index. Patients from D₂ and D₃ who received either radiotherapy alone or chemoradiation were used to validate pRiS as pr

SUBMITTER: Song B 

PROVIDER: S-EPMC10238543 | biostudies-literature | 2023 Jun

REPOSITORIES: biostudies-literature